关键词: ALK inhibitor Anti-proliferation activity NSCLC Structure modification

Mesh : Adenocarcinoma of Lung / drug therapy Anaplastic Lymphoma Kinase / antagonists & inhibitors chemistry Animals Antineoplastic Agents / chemical synthesis pharmacology therapeutic use toxicity Binding Sites Cell Line, Tumor Cell Proliferation / drug effects Drug Stability Female Fibroblasts / drug effects Humans Lung Neoplasms / drug therapy Mice, Inbred BALB C Microsomes, Liver / metabolism Molecular Docking Simulation Molecular Structure Phenylurea Compounds / chemical synthesis pharmacology therapeutic use toxicity Protein Kinase Inhibitors / chemical synthesis pharmacology therapeutic use toxicity Pyridines / chemical synthesis pharmacology therapeutic use toxicity Pyrimidines / chemical synthesis pharmacology therapeutic use toxicity Structure-Activity Relationship Xenograft Model Antitumor Assays

来  源:   DOI:10.1016/j.ejmech.2019.05.060   PDF(Sci-hub)

Abstract:
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for development of various tumor types. In this study, we synthesized a series of novel 2,4-diarylaminopyrimidine derivatives possessing a unique N-(3-pyridinylmethyl)urea moiety as ALK inhibitors. The most promising analog 5m bearing a 3-methoxy-4-morpholinophenyl substituent significantly inhibited proliferation of ALK positive H3122 and Karpas-299 cells with IC50 values about 10 nM, which were comparable with positive control LDK378. Compound 5m suppressed phosphorylation of ALK and its downstream proteins, and showed low cytotoxicity on normal human primary fibroblast cells (BJ cells). The binding mode of 5m was proposed by docking simulation, which explains the important role of N-(3-pyridinylmethyl)urea moiety. Furthermore, compound 5m exhibited favorable liver microsomal stability and significant efficacy in H3122 xenograft mice model. Interestingly, compound 5m also showed broader anti-proliferative activity on other human tumor cell lines, which was different from other ALK inhibitors.
摘要:
暂无翻译
公众号